uniQure (NASDAQ:QURE) Director Madhavan Balachandran Sells 11,685 Shares of Stock

uniQure N.V. (NASDAQ:QURE) Director Madhavan Balachandran sold 11,685 shares of the company’s stock in a transaction that occurred on Wednesday, June 17th. The stock was sold at an average price of $45.06, for a total value of $526,526.10. Following the transaction, the director directly owned 43,254 shares in the company, valued at $1,949,025.24. The trade was a 21.27% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Madhavan Balachandran also recently made the following trade(s):

• On Monday, June 15th, Madhavan Balachandran sold 10,000 shares of uniQure stock. The shares were sold at an average price of $27.85, for a total transaction of $278,500.00.
• On Thursday, June 11th, Madhavan Balachandran sold 1,993 shares of uniQure stock. The shares were sold at an average price of $27.06, for a total transaction of $53,930.58.

uniQure Stock Performance

QURE opened at $44.39 on Tuesday. uniQure N.V. has a 1-year low of $8.73 and a 1-year high of $71.50. The company has a market cap of $2.80 billion, a price-to-earnings ratio of -12.76 and a beta of 0.98. The company’s fifty day moving average price is $25.30 and its two-hundred day moving average price is $22.30. The company has a current ratio of 10.40, a quick ratio of 10.40 and a debt-to-equity ratio of 0.33.

uniQure (NASDAQ:QURE) last issued its quarterly earnings data on Tuesday, May 5th. The biotechnology company reported ($0.85) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.88) by $0.03. The firm had revenue of $3.56 million during the quarter, compared to analysts’ expectations of $5.21 million. uniQure had a negative net margin of 1,154.42% and a negative return on equity of 145.81%. On average, analysts expect that uniQure N.V. will post -3.64 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Torren Management LLC bought a new stake in uniQure in the 4th quarter worth about $28,000. Jones Financial Companies Lllp lifted its position in shares of uniQure by 509.0% during the 3rd quarter. Jones Financial Companies Lllp now owns 609 shares of the biotechnology company’s stock worth $33,000 after buying an additional 509 shares in the last quarter. IFP Advisors Inc bought a new position in shares of uniQure during the 4th quarter worth approximately $48,000. Smartleaf Asset Management LLC bought a new position in shares of uniQure during the 4th quarter worth approximately $48,000. Finally, CIBC Private Wealth Group LLC purchased a new position in shares of uniQure in the 3rd quarter worth approximately $50,000. 78.83% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of research firms have issued reports on QURE. Wolfe Research started coverage on uniQure in a research note on Monday, February 23rd. They set a “peer perform” rating for the company. TD Cowen reissued a “buy” rating on shares of uniQure in a research note on Tuesday, March 3rd. Barclays upgraded uniQure from an “equal weight” rating to an “overweight” rating and raised their target price for the company from $25.00 to $65.00 in a report on Thursday, June 18th. Cantor Fitzgerald raised uniQure from a “neutral” rating to an “overweight” rating and set a $61.00 target price on the stock in a research report on Wednesday, June 17th. Finally, Royal Bank Of Canada upped their price target on uniQure from $35.00 to $65.00 and gave the stock an “outperform” rating in a report on Thursday. Twelve investment analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $58.92.

uniQure News Summary

Here are the key news stories impacting uniQure this week:

• Positive Sentiment: uniQure reported initial AMT-260 data in temporal lobe epilepsy showing meaningful seizure reductions in early patients, with no treatment-related serious adverse events, which supports the company’s gene-therapy pipeline. Article Title
• Positive Sentiment: Early trial updates also highlighted seizure reductions of 79% to 100% in three patients, reinforcing investor optimism around AMT-260’s potential. Article Title
• Neutral Sentiment: The company also announced preliminary data from the first cohort in its Phase I/IIa AMT-260 clinical trial, a routine but important catalyst for a development-stage biotech. Article Title
• Negative Sentiment: uniQure announced a $150 million underwritten public offering, with an additional $22.5 million greenshoe option, which could dilute existing shareholders even if it strengthens the balance sheet. Article Title
• Negative Sentiment: Recent insider selling by the CEO and two directors may also weigh on sentiment, even though the transactions were made under pre-arranged 10b5-1 plans. Article Title

uniQure Company Profile

uniQure N.V. is a biotechnology company focused on the development and commercialization of gene therapies for patients with severe medical needs. Using its proprietary adeno‐associated viral (AAV) vector platform, the company designs single‐dose treatments aimed at addressing the underlying genetic causes of disease rather than solely managing symptoms. Its most advanced program, Hemgenix® (etranacogene dezaparvovec), received regulatory approval in the United States and Europe for adult patients with hemophilia B, marking one of the first gene therapies for a bleeding disorder to reach the market.

Beyond hemophilia B, uniQure’s pipeline includes preclinical and clinical-stage candidates targeting rare and debilitating conditions such as aromatic l-amino acid decarboxylase (AADC) deficiency, Huntington’s disease, and Parkinson’s disease.